Mitiglinide

Revision as of 15:40, 8 January 2007 by Pootbrer (talk) (added pubchem reference)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Mitiglinide
Mitiglinide.svg
Clinical data
Routes of
administration
oral
ATC code
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H25NO3
Molar mass315.41 g/mol

Mitiglinide (trade name Glufast®) is a drug for the treatment of type 2 diabetes.

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.

Dosage

Mitiglinide is delivered in tablet form.

External links


Linked-in.jpg